Our Portfolio

A groundbreaking foundry for CRISPR-driven cell therapy engineering

Core FoundrY

Artisan Research Labs

Artisan Development Labs

Artisan Cell Labs

  • Research
  • Lead Selection
  • Optimization
  • Characterization

Portfolio

  • Program #1
  • Program #2
  • Program #3
  • Program #4
  • Research
  • Lead Selection
  • Optimization
  • Characterization
  • IND enabling
  • Clinical

Artisan’s proprietary immune cell foundry allows for rapid progression through hit generation, lead selection, optimization, characterization, and candidate selection for targeted immune cell therapies.

Our platform can engineer and test combinatorial cell modifications simultaneously, enabling rapid and cost-effective generation of safer, more efficacious therapeutics. Artisan’s core foundry enables precision design, build, test, and learn cycles faster than ever before possible.

Artisan’s platform moves cell therapies to market faster

Our advanced platform enables rapid discovery and testing of many possible target genes for enhancement of therapeutic cell function. Leveraging in-house design algorithms and extensive experience, we rapidly and efficiently iterate on engineered cell builds, delivering world class solutions to the challenges of developing effective, safe, and accessible immune cell therapies.

We employ state-of the art analytical and process technologies to thoroughly characterize and optimize cell function and manufacturing, underpinning continuous learning and improvement to deliver the best cures.  Artisan’s product pipeline comprises multiple CRISPR engineered assets with industry leaders and in-house products that uniquely build on our foundry’s capabilities.

Scroll to see more of the table
Portfolio Indication Approach Research Lead Selection Lead Optimization & Characterization IND-Enabling Phase 1
partnership 1
not disclosed
CRispr engineered

partnership 2
not disclosed
CRispr engineered

partnership 3
not disclosed
CRispr engineered

Program 1
Blood Cancer
T-CELL: MULTIPLEX, ALLO, WITH NOVEL ENHANCEMENTS​

Program 1
Solid Tumor
T-CELL: MULTIPLEX, ALLO, WITH NOVEL ENHANCEMENTS​

Program 2
Blood, Solid Tumor
iPSC: MULTIPLEX, ALLO, + NOVEL ENHANCEMENTS

Program 3
Blood, Solid Tumor
NOVEL INNATE: MULTIPLEX, ALLO, + NOVEL ENHANCEMENTS